Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

---

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

---

WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET.

A live webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at https://www.pandiontx.com/. A replay of the webcast will be available shortly following the presentation.

About Pandion TherapeuticsPandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enables the company to create a pipeline of product candidates using immunomodulatory effector modules, with the ability to also combine an effector module with a tissue-targeted tether module in a bifunctional format. Pandion’s lead product candidate PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, is designed to selectively expand regulatory T cells systemically, without activating proinflammatory cells, such as conventional T cells and natural killer cells. Pandion is continuing to develop and expand its library of effector and tether modules as part of its earlier-stage research and discovery pipeline. For more information, please visit www.pandiontx.com and engage with us on Twitter @PandionTX or on LinkedIn.

For further information, please contact:

Media:Kathryn MorrisThe Yates Network914-204-6412kathryn@theyatesnetwork.com

Investors:Michelle AveryPandion Therapeutics857-273-0444investors@pandiontx.com 

Source: Pandion Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Checkmate Pharmaceuticals Presents New Clinical Trial Translational Data with Vidutolimod at the 2021 American Association for Cancer (AACR) Annual Meeting
• Greenbank Capital Portfolio Company Staminier Raises C$17m, and Completes Substantia Acquisition
• Global Arena Holding Files 10K – Highlighting Revenue Growth and Debt Reduction